Introduction to a cold extraction method for hash oil that preserves carboxylic acid form of cannabinoids THC and CBD
By Kate Welch, Pharm.D
The cannabinoids THCA and CBDA, short for delta-9 tetrahydrocannabinolic acid and cannabidiolic acid, respectively, are precursors to their more well-known and well-studied metabolites, THC (aka delta-9 tetrahydrocannabinol), the primary psychotropic cannabinoid found in cannabis, and CBD (cannabidiol), its primary non-psychotropic cannabinoid.
Found most abundantly in fresh cannabis plant material (Eichler et al. 2012; Turner et al. 1980), THCA and CBDA de-carboxylate the acidic part of the molecule into the active molecules THC and CBD. This occurs primarily by exposure to heat via smoking, cooking, or heated extraction of the dried or fresh plant, but also can form more slowly over time via extended exposure to light and atmosphere (Hazekamp 2008).
Until recently, THCA and CBDA were not considered to be able to survive metabolism (i.e. inhalation by the lungs or digestion by the stomach and intestines and processing by the liver); nor were they considered to have any pharmacological activity in and of themselves (Jung et al 2007; Takeda et al 2008).
However, recent in vitro and animal research using extracted THCA or CBDA reveals measurable actions on certain enzymes and receptor sites, suggesting some potential therapeutic effects for these cannabinoids and necessitating the elucidation and refinement of specific extraction techniques that preserve these particular acidic forms of these cannabinoids in order to provide material for further experimentation and research.
CBDA was the earliest discovered cannabinoid acid, in 1955 (Brenneisen 2002). As for THCA, there are actually two forms: THCA-A was isolated in 1965; THCA-B, an analogue, was isolated in 1975. Some plants express more of one or the other for unknown reasons (ElSohly and Gul 2014), but THCA-A is usually the most prominent, and the most studied (Brenneisen 2002). For the purposes of this article, THCA= THCA-A as found in the fresh or dried cannabis plant.
First, it is important to distinguish between the carboxylic acids that are precursors to THC and CBD in the fresh or dried plant material, and those that are the acid metabolites of smoked or ingested THC and CBD, formed in the liver or tissues and found in the bloodstream and filtered through the urine for excretion.
The primary non-psychoactive metabolite of THC is also an acid, 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (Foltz 2007). This metabolite forms via the enzyme alcohol dehydrogenase from the primary liver-produced metabolite of THC, the equally psychoactive 11-hydroxy-THC.
Removal of pure THC occurs rapidly from the bloodstream; 11-nor-9-carboxy-delta-9-THC accumulates and continues to form and be excreted into the urine as the THC in the bloodstream or from tissues that secrete stored THC into the bloodstream. As a result, urine drug assays intended for detection of human cannabis consumption primarily screen for the presence of this particular form of THCA (Chesher and Longo 2002).
Animal research confirms that biological enzymes do not themselves convert THCA to THC: pure THCA given to rats led to acid metabolites of THCA only, not THC or acid metabolites of THC (Jung 2007).
THCA and CBDA lack psychoactive effects (Kwong 2002) even when administered in pure form by IV to animals or humans (Grunfeld et al 1969). There is no evidence at this time that the acidic metabolites produced in vivo share the potential biological effects of its acidic precursors present in the fresh or dried plant.
Quantitative detection of THCA in raw plant material heretofore has primarily been intended to help predict the THC potency of a specific weight or volume of dried plant when it is eventually smoked or heated; liquid chromatography (HPLC) is preferred since it is important that the method of detection must not heat the sample which will immediately convert THCA to THC (Ambach et al 2014). Furthermore, lab analysis of this decarboxylation reaction provides estimates that smoking cannabis yields approximately a 30% conversion of THCA to active THC; other methods such as cooking or heated solvent extractions will yield 70-90% conversion (Dussy et al 2005). However, it is important to note that to date there is poor correlation between the percentage of THCA to THC conversion already present in a cannabis product to be consumed and the resulting pharmacokinetics (measurements in the bloodstream) or pharmacodynamics (measurable psychoactive or psychomotor effects) in humans. For example, a small study compared the levels of THC and THC metabolites (both active and inactive) in men who consumed a fixed amount of either a) a heated cannabis sativa extract; b) an unheated cannabis sativa extract; or c) pure pharmaceutical THC (aka dronabinol or Marinol®).
The unheated extract, surprisingly, turned out to provide both the highest CBD and THC blood levels on average, suggesting that whatever CBD and THC was initially ingested from the cold extract was readily absorbed and persisted in the bloodstream the longest. The heated extract, however, provided the highest total exposure to THC activity because of the sum of THC plus active metabolite 11-hydroxy-THC measured in the bloodstream. Both extracts measured blood levels of THC on average higher than in subjects given the pure pharmaceutical THC, even though both the unheated and heated cannabis extracts were CBDA dominant strain (CBDA/THCA ratio >1) (Eichler et al 2012).
While the above study provided some interesting evidence about the fate of CBD and THC after oral consumption from either heated or unheated extracts, it did not examine the pharmacokinetics or pharmacodynamics of CBDA or THCA, though there were more of these acidic forms of the cannabinoids present and ingested in the unheated extract than the heated one (and none present in the dronabinol). Thus, important questions remain about both the unique biological effects of these acidic cannabinoids on the human body as well as their potential entourage effects either kinetically or dynamically with their better-studied de-carboxylated metabolites.
Here is some of the most compelling evidence that shapes what we know about the carboxylic acid forms to date: both THCA and CBDA independently of any other phytocannabinoid, provide significant anti-nausea and anti-vomiting effects. In rats, THCA appears to be a considerable anti-nausea and anti-vomiting compound. In a study conducted in 2013, researchers determined not only that THCA was more potent compound in this regard than THC but also that THCA apparently mediated this response via 5HT1a (aka serotonin) receptors rather than the CB1 (cannabinoid) receptors whereby THC appears to exert its own anti-nausea effects as shown in other animal models (Rock 2013).
Researchers repeated similar experiments with CBDA as well, demonstrating that CBDA reduced both toxin and motion-induced nausea and vomiting in rats, via an as-yet-to-be-determined enhancement of 5HT-1A serotonin receptor activation (Bolognini et al 2013). Unlike the THCA experiment-- which showed THCA and THC exerting anti-nausea effects via wholly different receptor mechanisms--CBDA appears in vivo and in vitro to work pharmacologically more similarly to CBD (e.g. both via serotonin-receptor activation), though CBDA was shown to be more potent than CBD in its serotonin-receptor-mediated effects.
Additionally, CBDA and THCA have been shown in vitro to block, in varying degrees, both cyclooxygenase (COX) enzymes 1 and 2, which are each distinct mediators of inflammation and pain secondary to inflammation. Non-steroidal anti-inflammatory (NSAID) drugs such as acetylsalicylic acid (aspirin), ibuprofen, naproxen, indomethacin, and diclofenac all work via COX 1 and 2 inhibition, and, like CBDA and THCA, contain a carboxylic acid group in their structures that suggests this part of the molecule is integral to the way they work.
In one assay, CBDA but not THCA significantly inhibited both COX 1 and 2-mediated oxidation activity, with the CBDA showing a strong preference for inhibiting COX 2 specifically (Takeda et al. 2008).
A second study demonstrated that both THCA and CBDA inhibited COX 1 significantly but only THCA inhibited COX 2, and by only a little over 30% (Ruhaak, L. et al 2011).
Both studies showed that the carboxylic acid forms CBDA and THCA had stronger overall COX-inhibiting activity than their de-carboxylated forms CBD and THC, however. More research is needed to clarify the role the acidic cannabinoids play in moderating inflammation and determine whether or not they may be safer alternatives for this than NSAIDs, which have well-known dose-dependent or long-term use detrimental effects on the gastrointestinal and cardiovascular systems due to their COX inhibition.
Lastly, both CBDA and THCA show in vitro activity at some of the various cation channel receptors collectively known as transient receptor potentials that play important roles in pain and inflammation signal transduction such as TRPV1 and TRPV4(the “vanilloid” type); TRPA1(the “ankyrin” type) and TRPM8 (the “melastatin” type). They can block, activate, or de-sensitize these to activation by another activator (Cascio and Pertwee 2014). These are likely additional mechanisms by which the carboxylic acid forms of the cannabinoids work independently of their de-carboxylated forms to moderate pain and inflammation both centrally and peripherally.
The carboxylic acid cannabinoids CBDA and THCA are likely to be important contributors to the relief of nausea, inflammation, and pain that humans have attributed to the cannabis plant for millennia. What makes them worth studying individually today are not only their individual roles within the entourage of effects that cannabis is so well known for, but also in their ability to relieve nausea or pain alone while bypassing the sometimes debilitating or unwanted psychoactive effects produced by cannabinoids like THC that activate the CB1 receptor.
The recent popularity of websites and electronically-published books extolling the benefits of juicing of fresh cannabis leaf or whole plants to treat a variety of ailments are likely attributable to the role that CBDA and THCA play on various biological targets as enumerated above.
CBDA and THCA can also be extracted and purified out of most any other cannabis extract (Wohlfarth et al 2011) but, short of the capabilities of sophisticated chemical separation of CBDA and THCA from all other cannabinoids in a lab, one will most easily obtain an extract with a much higher percentage of the carboxylic acid cannabinoids via cold-process extracts of the fresh plant. The resulting extract must continue to be stored in a cool, dark place (Taschwer 2015) in order to preserve its unique characteristics, and should be ingested rather than smoked if the goal of therapy includes reducing the psychoactive effects produced by THC.
Ambach, L. et al. Simultaneous quantification of delta-9-THC, THC-acid A, CBN and CBD in seized drugs using HPLC-DAD. Forensic Sci Int 2014 Oct; 243:107-11. Brenneisen, R. Pharmacokinetics. Cannabis and the Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential.” Grotenhermen and Russio, eds NY: The Haworth Press, 2002. Bolognini, D. et al. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behavior in rats by enhancing 5-HT1A receptor activation. Br Journ Pharmacology (2013) 168; 11456-1470.
Cascio and Pertwee. Known Pharmacological Actions of Nine Nonpsychotropic Phytocannabinoids. Pertwee, ed.. Handbook of Cannabis London: Oxford U Press, 2014. Chesher, G. and Longo, M. Cannabis and Alcohol in Motor Vehicle Accidents. Grotenhermen and Russo, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential New York: Haworth Press, 2002. De Petrocellis, L. et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011 Aug;163(7):1479-94.
Dussy, F.E. et al. Isolation of Delta9-THCA-A from hemp and analytical aspects concerning the determination of Delta9-THC in cannabis products. Forensic Sci Int. 2005 Apr 20; 149(1):3-10. Eichler, M. et al. “Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Med 2012 May; (70)7:686-91. ElSohly, M. and Gul, W. Constituents of Cannabis Sativa. Handbook of Cannabis, ed. R.Pertwee; Oxford U Press: 2014
Foltz, Rodger. Mass Spectromic Methods for Determination of Cannabinoids to Physiological Specimens. Marijuana and the Cannabinoids, ed. M. ElSohly 2007. Grunefeld et al. Psychopharmacological Activity of Some Substances Extracted from Cannabis sativa. Electroencephalography and Clinical Neurophys 27(2);219-220. 1969. Hazekamp, A. Cannabis Review. Department of Plant Metabolomics, Leiden University, 2008-9. Jung, J. et al. Detection of Delta9-tetrahydrocannabinolic acid A in human urine and blood serum by LC-MS/MS. J Mass Spectrom 2007: Mar; 42(3): 354-60.
Raikos et al. Determination of Δ9-tetrahydrocannabinolic acid A (Δ9-THCA-A) in whole blood and plasma by LC-MS/MS and application in authentic samples from drivers suspected of driving under the influence of cannabis. Forens Sci Int 2014 Oct 243:130-6. Rock, E. and Parker, L. Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. Br J Pharmacol. 2013 Jun;169(3):685-92
Rock, E. et al. Tetryahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus Br J Pharmacol 2013 170:641-48. Rock, E. et al. A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping Psychopharmacology 2014 Aug;231(16):3207-15.
Takeda, S. et al. Cannabidiolic Acid as a selective Cyclooxygenase-2 inhibitory component in cannabis. Drug Metab Disp 2008; 36(9):1917-21.
Taschwer, M. and Schmid, M. Determination of the relative percentage distribution of THCA and Δ(9)-THC in herbal cannabis seized in Austria - Impact of different storage temperatures on stability. Forensic Sci Int. 2015 Sep;254:167-71.
Turner et al. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Natural Prod 1980 Mar-Apr; 43(2): 169-234.
Wohlfarth, A. et al. Rapid isolation procedure for Δ9-tetrahydrocannabinolic acid A (THCA) from Cannabis sativa using two flash chromatography systems. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Oct 15;879(28):3059-64